SGLT-2 Inhibitors: An Emerging Therapeutic Class in the Treatment of Diabetes — Part 1 of 2

Summary: <p>CME credits: 0.50 Valid until: 11/26/2014 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6860</p><p>In early 2012, the ADA and the EASD issued a joint position statement emphasizing patient specific treatment of hyperglycemia for T2DM. The impetus underlying the new guidelines was the growing appreciation of the complexity surrounding contemporary glycemic management in patients with T2DM. Factors complicating management include the increasing number and variety of available pharmacotherapy agents, potential adverse effects, and new uncertainties concerning the effects of intensive glycemic control on macrovascular complications.<br><br>Notwithstanding, the ability of many physicians to adequately select and intensify T2DM treatment regimens has been historically poor, suffering from lack of confidence in managing complex combinations of agents across myriad patient demographics and comorbid conditions. SGLT-2 inhibitors are among the emerging therapeutic classes for managing T2DM and have a number of interesting properties.</p> <p><span style="color: #ff0000;"><em>On January 8, 2014, after launch of this CME activity, FDA approved the SGLT-2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes. On September 19, 2014 an another drug received FDA approval of Trulicity to also treat type 2 diabetes. Canagliflozin, the first approved SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, was approved by FDA on March 29, 2013. </em></span><br><br><strong>Estimated time to complete activity:</strong> 30 minutes</p> <p>After you have complete this activity, click below to participate in the second part of this series:</p> <ul> <li> <a href="../cmedetails.aspx?sid=6861">Part 2 with Vivian Fonseca, MD</a><br><br> </li> </ul>